IMAC (BACK) Competitors $0.06 0.00 (0.00%) As of 07/25/2025 01:28 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock BACK vs. BTTX, UPHL, ACONW, AONC, DHACW, LFMDP, OTRKP, PIIIW, TALKW, and TOIIWShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), Talkspace (TALKW), and Oncology Institute (TOIIW). These companies are all part of the "healthcare" industry. IMAC vs. Its Competitors Better Therapeutics UpHealth Aclarion American Oncology Network Digital Health Acquisition LifeMD Ontrak P3 Health Partners Talkspace Oncology Institute IMAC (NASDAQ:BACK) and Better Therapeutics (NASDAQ:BTTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings. Do insiders and institutionals have more ownership in BACK or BTTX? 5.8% of IMAC shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 12.3% of IMAC shares are owned by insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, BACK or BTTX? IMAC has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Better Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Does the media refer more to BACK or BTTX? In the previous week, IMAC had 3 more articles in the media than Better Therapeutics. MarketBeat recorded 3 mentions for IMAC and 0 mentions for Better Therapeutics. Better Therapeutics' average media sentiment score of 0.00 beat IMAC's score of -0.06 indicating that Better Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment IMAC Neutral Better Therapeutics Neutral Which has better earnings & valuation, BACK or BTTX? IMAC has higher revenue and earnings than Better Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$72.05K1.73-$9.42MN/AN/ABetter TherapeuticsN/AN/A-$39.76MN/AN/A Is BACK or BTTX more profitable? Company Net Margins Return on Equity Return on Assets IMACN/A N/A -325.44% Better Therapeutics N/A N/A N/A SummaryIMAC and Better Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BACK vs. The Competition Export to ExcelMetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$124K$124K$5.70B$9.50BDividend YieldN/AN/A4.60%4.01%P/E RatioN/AN/A28.1020.06Price / Sales1.731.73429.3889.33Price / CashN/AN/A36.2258.56Price / Book-0.09N/A8.665.87Net Income-$9.42M-$9.42M$3.25B$258.55M7 Day PerformanceN/AN/A4.22%3.73%1 Month PerformanceN/AN/A10.51%11.75%1 Year PerformanceN/AN/A34.40%18.02% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BACKIMACN/A$0.06flatN/A-96.5%$124K$72.05K0.00180BTTXBetter TherapeuticsN/A$0.00flatN/A-66.7%$5KN/A0.0040UPHLUpHealthN/A$0.00flatN/A-100.0%$4K$130M0.001,750ACONWAclarionN/A$0.02+4.1%N/A-9.7%$0.00$54.60K0.007Positive NewsGap UpAONCAmerican Oncology NetworkN/A$10.00+1.0%N/A+381.6%$0.00$1.34B0.001,520News CoverageGap DownDHACWDigital Health AcquisitionN/A$0.04flatN/A-63.7%$0.00N/A0.00N/AGap UpLFMDPLifeMDN/A$23.15-0.3%N/A+9.7%$0.00$234.01M0.00230Positive NewsOTRKPOntrakN/A$0.26+13.3%N/A+41.9%$0.00$10.84M0.00250Gap DownPIIIWP3 Health PartnersN/A$0.01+20.5%N/A-65.7%$0.00$1.49B0.00500Gap DownTALKWTalkspaceN/A$0.08+15.1%N/A-20.8%$0.00$194.36M0.00500Positive NewsGap DownTOIIWOncology InstituteN/A$0.09-1.0%N/AN/A$0.00$403.15M0.00660Positive NewsGap Up Related Companies and Tools Related Companies Better Therapeutics Competitors UpHealth Competitors Aclarion Competitors American Oncology Network Competitors Digital Health Acquisition Competitors LifeMD Competitors Ontrak Competitors P3 Health Partners Competitors Talkspace Competitors Oncology Institute Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BACK) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s #1 America First StockAmerica’s industrial comeback is underway — and it’s bigger than anyone expected. Over $5 trillion has alre...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
